IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors

PURPOSE: Somatic mutations in IDH1/2 occur in ~20% of patients with myeloid neoplasms, including acute myeloid leukemia (AML). IDH1/2(MUT) enzymes produce D-2-hydroxyglutarate (D2HG), which associates with increases in DNA damage and improved responses to chemo/radiotherapy and PARP inhibitors in so...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Molenaar, Remco J., Radivoyevitch, Tomas, Nagata, Yasunobu, Khurshed, Mohammed, Przychodzen, Bartolomiej, Makishima, Hideki, Xu, Mingjiang, Bleeker, Fonnet E., Wilmink, Johanna W., Carraway, Hetty E., Mukherjee, Sudipto, Sekeres, Mikkael A., van Noorden, Cornelis J.F., Maciejewski, Jaroslaw P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5884732/
https://ncbi.nlm.nih.gov/pubmed/29339439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2796
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados